Related Experiment Video
Updated: Aug 11, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
[The vasoactive action of kurantil in patients with chronic glomerulonephritis]
Insights
Curantyl (C) treatment offers immediate benefits for chronic glomerulonephritis (ChGN) patients through its vasoactive and antiaggregant effects. Late results show sustained health improvements and slowed disease progression in a significant portion of patients.
Area of Science:
- Nephrology
- Pharmacology
- Internal Medicine
Background:
- Chronic glomerulonephritis (ChGN) is a progressive kidney disease.
- Effective treatment strategies for ChGN are crucial for managing patient outcomes.
- Curantyl (C) is a medication with known vasoactive and antiaggregant properties.
Purpose of the Study:
- To evaluate the immediate and late therapeutic effects of Curantyl (C) in patients with chronic glomerulonephritis (ChGN).
- To identify patient subgroups that benefit most from Curantyl (C) treatment.
- To assess the long-term impact of Curantyl (C) on ChGN progression.
Main Methods:
- A 3-4 week course of Curantyl (C) treatment was administered to ChGN patients.
- Immediate treatment outcomes were assessed.
- Late results were analyzed 1.5-2 years after Curantyl (C) withdrawal.
- Comparison with a control group was performed.
Main Results:
- Immediate positive effects of Curantyl (C) were attributed to its vasoactive and antiaggregant actions.
- A negative immediate outcome, "steal syndrome," was observed in some patients.
- Curantyl (C) was effective in ChGN patients with predominant fibroplastic changes, hypertension (grade I), and early-stage disease.
- Late analysis revealed health status improvement in 22.5% and slowed ChGN progression in 15% of patients compared to controls.
Conclusions:
- Curantyl (C) demonstrates both short-term benefits and potential long-term advantages in managing chronic glomerulonephritis (ChGN).
- Careful patient selection is advised due to potential side effects like "steal syndrome."
- Further research may explore optimizing Curantyl (C) use for sustained ChGN management.
Abstract:
The immediate positive result of 3-4 weeks' course of treatment with curantyl (C) of patients with chronic glomerulonephritis (ChGN) is due to both vasoactive and antiaggregant action of the preparation. The negative immediate result of C treatment appear to be associated with <
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
08:44Elucidation of the Material Basis of Yiqi Qingjie Formula Against IgA Nephropathy Using UHPLC-Q-Orbitrap HRMS Integrated with Network Pharmacology
Published on: May 19, 2026
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Antihypertensive Drugs: Action of Diuretics
Estimation of k and VD of Aminoglycosides
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care